Products Tolterodine is commercially available in the form of sustained-release capsules (Detrusitol SR). It has been approved in many countries since 2000. Its successor product, fesoterodine (Toviaz), was launched in 2008 and desfesoterodine (Tovedeso) in 2019. A non-retarded preparation is also commercially available in the United States (Detrol). Structure and properties Tolterodine (C22H31NO, Mr = … Tolterodine
Products Trospium chloride is commercially available in the form of dragées (Spasmo-Urgenin Neo, Spasmex). It has been approved in many countries since 1983. Structure and properties Trospium chloride (C25H30ClNO3, Mr = 428.0 g/mol) is a quaternary amine that exists as a chloride salt. It is a fine, colorless to slightly yellow, crystalline substance. Trospium chloride … Trospium Chloride
Symptoms Irritable bladder manifests itself in the following symptoms. By definition, there are no pathologic changes of the genitourinary tract: Strong urge to urinate, which is difficult to suppress. Increased urinary frequency during the day Nighttime urination Urinary incontinence: an involuntary loss of urine may occur The constant urge reduces the quality of life and … Hyperactive Bladder
Symptoms Urinary incontinence manifests as involuntary leakage of urine. The common problem poses a psychosocial challenge for those affected, which can lead to changes in personal activities and a loss of quality of life. Risk factors include female gender, age, obesity, and numerous medical conditions. Causes Urinary incontinence can occur as a result of pathologic, … Urinary Incontinence: Causes and Treatment
Products Desfesoterodine was approved in many countries in 2019 in sustained-release tablet form (generic, tovedeso). Structure and properties Desfesoterodine (C22H31NO2, Mr = 341.5 g/mol) is the active metabolite of the prodrug fesoterodine as well as tolterodine (detrusitol). It is also referred to as 5-hydroxymethyltolterodine. In the drug, it is present as desfesoterodine succinate. Effects Desfesoterodine … Desfesoterodine
Products Oxybutynin is commercially available in tablet form and as a transdermal patch (Ditropan, Kentera). It has been approved in many countries since 1988, and the transdermal patch has been available since 2007. Extemporaneous formulations are also produced; see Intravesical oxybutynin solution (for use in the urinary bladder). Other dosage forms have been released in … Oxybutynin
Products Flavoxate is commercially available in the form of film-coated tablets (Urispas). It has been approved in many countries since 2008. Structure and properties Flavoxate (C24H25NO4, Mr = 391.5 g/mol) is present in drugs as flavoxate hydrochloride, an oxo-benzopyran and piperidine derivative. An active metabolite is involved in the effects. Effects Flavoxate (ATC G04BD02) has … Flavoxat
